SLN vs. AVXL, ABUS, EOLS, KALV, ANAB, COGT, ABCL, TRVI, SION, and CDXC
Should you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include Anavex Life Sciences (AVXL), Arbutus Biopharma (ABUS), Evolus (EOLS), KalVista Pharmaceuticals (KALV), AnaptysBio (ANAB), Cogent Biosciences (COGT), AbCellera Biologics (ABCL), Trevi Therapeutics (TRVI), Sionna Therapeutics (SION), and ChromaDex (CDXC). These companies are all part of the "pharmaceutical products" industry.
Silence Therapeutics vs. Its Competitors
Silence Therapeutics (NASDAQ:SLN) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
Silence Therapeutics has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.
Silence Therapeutics presently has a consensus target price of $33.83, indicating a potential upside of 545.67%. Anavex Life Sciences has a consensus target price of $44.00, indicating a potential upside of 436.59%. Given Silence Therapeutics' higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Anavex Life Sciences.
Anavex Life Sciences has lower revenue, but higher earnings than Silence Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Silence Therapeutics and Silence Therapeutics both had 4 articles in the media. Anavex Life Sciences' average media sentiment score of 1.53 beat Silence Therapeutics' score of 1.18 indicating that Anavex Life Sciences is being referred to more favorably in the news media.
98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are held by institutional investors. 4.1% of Silence Therapeutics shares are held by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Anavex Life Sciences received 397 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 78.95% of users gave Silence Therapeutics an outperform vote while only 74.92% of users gave Anavex Life Sciences an outperform vote.
Anavex Life Sciences has a net margin of 0.00% compared to Silence Therapeutics' net margin of -342.00%. Anavex Life Sciences' return on equity of -37.50% beat Silence Therapeutics' return on equity.
Summary
Anavex Life Sciences beats Silence Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Silence Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silence Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SLN) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy SLN Stock Free SLN Stock Alerts